




The relative strengths and weaknesses of Summit Therapeutics Inc are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Summit Therapeutics Inc compared to the market average is the variable Liabilities, increasing the Economic Capital Ratio by 50% points. The greatest weakness of Summit Therapeutics Inc is the variable Research and Development, reducing the Economic Capital Ratio by 29% points.

The company's Economic Capital Ratio, given in the ranking table, is 298%, being 41% points above the market average of 256%.

Input Variable	Value in 1000 USD	Output Variable	Value in 1000 USD
Assets, Current	87,674	Assets	102,498
Cost of Goods Sold	0	Liabilities	23,045
Intangible Assets	13,545	Expenses	73,152
Liabilities, Current	19,890	Revenues	20,172
Liabilities, Non-Current	3,155	Stockholders Equity	79,453
Other Assets	554	Net Income	-52,697
Other Compr. Net Income	970	Comprehensive Net Income	-52,212
Other Expenses	646	BaseVar	110,060
Other Liabilities	0	ECR before Limited Liability	193%
Other Net Income	283	Economic Capital Ratio	298%
Other Revenues	20,172		
Property and Equipment	725		
Research and Development	53,274		
Selling, General and Administrative Expense	19,232		